Patients with vascular disease have significantly higher concentrations of plasma total cysteine (tCYS) than do healthy individuals (1-7 ). The present method is a new, rapid, and sensitive enzymatic colorimetric assay for tCYS in plasma samples and is homogeneous in that it avoids separation methods. The tCYS assay uses only the recombinant enzymes methionine ␣,␥-lyase (rMETase) and Sadenosylhomocysteine hydrolase (rSAHH) cloned from Pseudomonas putida and Trichomonas vaginalis, respectively. We have also developed enzymatic assay methods for total homocysteine (tHCY) (8, 9 ) and vitamin B 6 (10 ) in plasma that use the same analyte, H 2 S, that is used for tCYS in the present report. Simultaneous assay of tHCY, vitamin B 6 , and tCYS may be relevant to the study for the occurrence and prevalence of cardiovascular disease (11 ).
Patients with vascular disease have significantly higher concentrations of plasma total cysteine (tCYS) than do healthy individuals (1) (2) (3) (4) (5) (6) (7) . The present method is a new, rapid, and sensitive enzymatic colorimetric assay for tCYS in plasma samples and is homogeneous in that it avoids separation methods. The tCYS assay uses only the recombinant enzymes methionine ␣,␥-lyase (rMETase) and Sadenosylhomocysteine hydrolase (rSAHH) cloned from Pseudomonas putida and Trichomonas vaginalis, respectively. We have also developed enzymatic assay methods for total homocysteine (tHCY) (8, 9 ) and vitamin B 6 (10 ) in plasma that use the same analyte, H 2 S, that is used for tCYS in the present report. Simultaneous assay of tHCY, vitamin B 6 , and tCYS may be relevant to the study for the occurrence and prevalence of cardiovascular disease (11 ) .
The instrumentation included a Hitachi U-2000 Spectrophotometer (Hitachi, Ltd.) and Fl-1000 fluorescence spectrophotometer and a Hitachi HPLC (L-6200A Intelligent Pump) equipped with a Supelcosil LC-18DB column [25 cm ϫ 4.8 mm (i.d.); particle size, 5 m; Supelco].
The chemicals used were l-cysteine, d,l-homocysteine, l-methionine, adenosine (ADO), l-dithiothreitol, Triton X-100, pyridoxal 5-phosphate, and potassium ferricyanide and were purchased from Sigma Chemical Co. N,NDibutylphenylenediamine (DBPDA) was synthesized in our laboratory (8, 9, 12 ) . rMETase and SAHH were produced in our laboratory (13, 14 ) .
Four reagents were used for the assay. Reagent 1 contained 20 mmol/L potassium phosphate (pH 8.3), 150 mmol/L NaCl, 9 mg/L rSAHH, 2 mL/L Triton X-100, 1.0 mmol/L l-dithiothreitol, and 100 mol/L ADO. Reagent 2 contained rMETase (1.08 g/L protein) in 20 mmol/L potassium phosphate (pH 7.2). Reagent 3 contained 40 mmol/L DBPDA in 3 mol/L HCl. Reagent 4 contained 15 mmol/L potassium ferricyanide in 20 mmol/L potassium phosphate (pH 7.2).
Whole blood was collected in evacuated blood-collection tubes without additive or containing EDTA, heparin, or citrate as anticoagulants. Centrifugation was carried out as soon as possible at 2000g for 10 min. The plasma was collected and stored at Ϫ70°C until analysis.
The principle of the assay is as follows: In step 1, samples are reduced by l-dithiothreitol to generate free reduced CYS and HCY. Simultaneous use of rSAHH with excess ADO converts the reduced HCY to S-adenosylhomocysteine (SAH).
Step 1:
In step 2, rMETase is added to generate H 2 S from tCYS:
Step 2: Reduced CYS O ¡ rMETase Pyruvate ϩ H 2 S ϩ NH 3
In step 3, H 2 S combines with DBPDA to form a compound that is fluorescent and has ultraviolet absorbance. For this assay, the absorbance is read at 675 nm.
Step 3: DBPDA ϩ H 2 S O ¡ K 3 Fe(CN) 6 3,7-bis(dibutylamino)-phenothiazine-5Ј-ium chloride
The tCYS enzymatic assay protocol was as follows:
Step 1. To remove the tHCY in samples, 20 L of calibrator or plasma sample and 980 L of reagent 1 were added. This reaction was carried out at 37°C for 30 min. This reaction was essential for release of HCY from disulfide linkages in plasma proteins and its removal to form S-adenosylhomocysteine.
Step 2. For production of H 2 S from tCYS by rMETase, reagent 2 (10 L) was added to the tubes, which were then vortex-mixed and incubated at 37°C for 10 min.
Step 3. For the chromogenic reaction, the enzymatic reaction was stopped by addition of 50 L of reagent 3 followed by 50 L of reagent 4. The chromogenic reaction was carried out at 37°C for 10 min. tCYS was measured by its absorbance at 675 nm. Calibration was performed with use of calibrators before the first run every day. The HPLC assay for tCYS and tHCY used the ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate derivatization method as described by Ubbink et al. (15 ) and Dudman et al. (16 ) with some modifications. Plasma samples were reduced with tri-n-butylphosphine and then derivatized with ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate. tCYS was measured by HPLC with a reversed-phase Supelcosil LC-18DB column at room temperature.
Within-run imprecision was calculated by measuring tCYS in duplicate 20 times. The imprecision (CV) was 4.3% at a mean tCYS concentration of 189.1 mol/L and 4.5% at a mean tCYS concentration of 283.4 mol/L. Between-run imprecision was based on results from 20 successive analyses performed over 20 days. The imprecision (CV) was 4.9% and 4.7% at mean tCYS concentrations of 189.1 and 283.4 mol/L, respectively.
To examine the linearity of the calibration curve, we measured five different l-CYS solutions (10, 62.5, 125, 250, and 500 mol/L) with the tCYS enzymatic assay. The calibration curve was linear between 10 and 500 mol/L, and linear regression analysis gave a relationship of: y ϭ 0.0005x ϩ 0.0008 mol/L (r 2 ϭ 0.9973). The analytical recoveries for crystalline L-CYS added to pooled human plasma were determined. L-CYS (50 -200 mol/L) was added to the plasma samples containing 153 mol/L endogenous L-CYS. The mean recovery was ϳ99%.
Technical Briefs
Clinical Chemistry 50, No. 7, 2004 The tCYS concentrations in 40 different human plasma samples were measured with the tCYS enzymatic assay and a conventional HPLC method. As shown in Fig. 1 , the methods showed excellent agreement. Deming regression analysis (17 ) comparing the enzymatic assay (x) and the HPLC method (y) yielded the following: y ϭ 1.0054x Ϫ 0.6716 (r 2 ϭ 0.93; n ϭ 40). The mean difference between the methods, as determined by Bland-Altman difference plot (18 ) of paired means of the enzymatic and HPLC tCYS assays, was 0.645 mol/L.
We tested the interference in the enzymatic tCYS assay by adding L-HCY, l-methionine, l-cystathionine, and cysteinylglycine to plasma samples. This experiment tested the cross-reactivity of rMETase to potentially interfering compounds (Table 1) . No interference by HCY up to 200 mol/L, l-methionine up to 100 mol/L, lcystathionine up to 130 mol/L, and cysteinylglycine up to 200 mol/L was observed. This is expected because of the high specificity of rMETase (19 ) . To test whether the assay was influenced by hemolysis, bilirubin, and triglycerides, we added different concentrations of hemoglobin, bilirubin, and triglycerides to the plasma preparation. Abnormalities in the expression of specific genes have been linked to a large and increasing number of diseases. Quantification of gene expression is a promising basis for early diagnosis, but analysis at the mRNA level has shown to be difficult because of the limited sensitivity of existing nucleic-acid-detection techniques. The most commonly used methods for quantification of gene expression include Northern blotting (1 ), ribonuclease protection assays (RPAs) (2 ), and reverse transcription-polymerase chain reaction (RT-PCR) (3, 4 ) . The main limitation of the first two techniques is their relatively low sensitivity. RT-PCR can theoretically amplify a single nucleic acid molecule millions of times, but optimization of primer sets prolongs the assay time, and different genes in a starting mRNA mixture may not be present in the same amounts in the final RT-PCR products because of selective and nonlinear target amplification (5 ). These limitations affect the precision and quality of the resulting data and often provide distorted information on gene expression. Sensitive, reliable gene detection is one of the challenges in molecular diagnostics.
Electrochemical detection provides a simple, accurate, and inexpensive platform for molecular diagnostics. Despite the enormous progress made in electrochemical nucleic acid biosensor research in the past 5 years, to be one step closer to commercialization, this research must overcome several important hurdles. The first is validation of the biosensor results on a statistically large population of real samples rather than the commonly reported relatively short synthetic oligonucleotides (6 ) . Another challenge is to multiplex the electrochemical biosensors into useful sensor arrays. Typically, arrays of 30 -100 sensors are needed for diagnostic purposes. For example, breast cancer screening requires the testing of 20 -30 cancer susceptibility genes plus positive and negative controls (7 ) . Of the many proposed electrochemical detection schemes, only a few attempts have been made to detect gene expression at the mRNA level (8 ) .
Here we describe an ultrasensitive method for direct detection of expression of breast cancer susceptibility genes in human breast tissues on an 8 ϫ 8 sensor array. The human breast tissues were stored in liquid nitrogen immediately after surgery until mRNA extraction. Tissues were mechanically homogenized, and mRNA was extracted by use of a Dynabeads ® mRNA DIRECT TM Kit (Dynal ASA) according to the manufacturer's protocol. Labeling of the mRNA was carried out with cisplatincoupled biotin conjugates (Biotin-Chem-Link TM ; Roche Diagnostics) according to the manufacturer's recommended procedure. All solutions were treated with diethyl pyrocarbonate, and surfaces were decontaminated with RNaseZap (Ambion).
To fabricate the sensor array, we evaporated a titanium adhesion layer (25-50Å) on a glass slide by use of an electron beam, followed by 2500 -3000 Å of gold. A patterned 1-mm thick adhesive spacing/insulating layer with a screen-printed Ag/AgCl layer and a hydrophobic layer were assembled on the top of the slide (Fig. 1 in the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/content/ vol50/issue7/). The diameter of the individual sensor was 2.0 mm, and that of the top hydrophobic pattern was 4 mm. We immobilized 24mer oligonucleotides on each individual sensor surface, which served as capture probes, as described previously (9 ) . The sequences of the captured probes were complementary to the sequence of each gene in a region specific to that gene where no mutation has been reported.
We examined breast cancer susceptibility genes, i.e., tumor protein p53 (TP53; 1182 bp), heat-shock protein 90 (HSP90; 1632 bp), breast cancer gene 1 (BRCA1; 5592 bp), and Histone H4 (His4; 312 bp), plus a housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1008 bp), covering both high-/low-copy number and long/short genes. Hybridization was carried out in a 55°C water bath in a buffer containing 10 mmol/L Tris-HCl, 1.0 mmol/L EDTA, and 0.10 mol/L NaCl for 30 min. Before the hybridization, nucleic acid samples were denatured at 95 (cDNA) and 70°C (mRNA) for 10 min and cooled in an ice bath before being added to the sensor array. After hybridization, the sensor array was exposed to 2.5-L aliquots of 5.0 g/L glucose oxidase-avidin at room temperature for 30 min and then to 2.5-L aliquots of 5.0 g/L redox polymer, poly(vinylimidazole-co-acrylamide) partially imidazole-complexed with Os(2,2Ј-bipyridine) 2 (imidazole) for 10 min. Synthesis of the redox polymer has been described elsewhere (10 ) . The formation of a mixed micro three-dimensional mRNA ϩ glucose oxidase-avidin/redox polymer bilayer allowed elecClinical Chemistry 50, No. 7, 2004 
